Dermatology and therapy · 2025
Management and Burden of Hidradenitis Suppurativa: An Italian Hybrid Real-World Study.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Balato Anna, Venturini Marina, Scalvenzi Massimiliano, Foti Caterina, Maifredi Giovanni, Creazzola Simona Serao, Antonacci Stefania, Tonelli Arianna, Valsecchi Diletta, Vassellatti Donatella, Cipelli Riccardo, Ori Alessandra, Casoli Lucia
Аннотация
INTRODUCTION: Hidradenitis suppurativa (HS) is a chronic, inflammatory skin disease that severely impacts quality of life and carries a substantial economic burden.
METHODS: This multicenter observational study generated real-world evidence on HS in Italy, focusing on clinical profiles, management, and costs. Data were collected from 50 adults at four specialized centers, combining primary data with retrospective administrative data.
RESULTS: Patients with moderate-to-severe disease had longer diagnostic delays (median 1.8 versus 0.7 years), lower symptom control (40.7% versus 95.2%), and worse quality of life (Dermatology Life Quality Index: 11.8 versus 8.0) than those with mild disease. Furthermore, HS was associated with higher costs in moderate-to-severe cases, including greater direct (€2214 versus €873) and indirect expenses (€2435 versus €262).
CONCLUSIONS: The findings highlight the social and economic burden of HS and emphasize the need for increased healthcare awareness for earlier diagnosis and better management.
METHODS: This multicenter observational study generated real-world evidence on HS in Italy, focusing on clinical profiles, management, and costs. Data were collected from 50 adults at four specialized centers, combining primary data with retrospective administrative data.
RESULTS: Patients with moderate-to-severe disease had longer diagnostic delays (median 1.8 versus 0.7 years), lower symptom control (40.7% versus 95.2%), and worse quality of life (Dermatology Life Quality Index: 11.8 versus 8.0) than those with mild disease. Furthermore, HS was associated with higher costs in moderate-to-severe cases, including greater direct (€2214 versus €873) and indirect expenses (€2435 versus €262).
CONCLUSIONS: The findings highlight the social and economic burden of HS and emphasize the need for increased healthcare awareness for earlier diagnosis and better management.